Your browser doesn't support javascript.
loading
First-in-human study to evaluate safety, tolerability, and immunogenicity of heterologous regimens using the multivalent filovirus vaccines Ad26.Filo and MVA-BN-Filo administered in different sequences and schedules: A randomized, controlled study.
Bockstal, Viki; Shukarev, Georgi; McLean, Chelsea; Goldstein, Neil; Bart, Stephan; Gaddah, Auguste; Anumenden, Dickson; Stoop, Jeroen N; Marit de Groot, Anne; Pau, Maria G; Hendriks, Jenny; De Rosa, Stephen C; Cohen, Kristen W; McElrath, M Juliana; Callendret, Benoit; Luhn, Kerstin; Douoguih, Macaya; Robinson, Cynthia.
Affiliation
  • Bockstal V; Janssen Infectious Diseases and Vaccines, Leiden, The Netherlands.
  • Shukarev G; Janssen Infectious Diseases and Vaccines, Leiden, The Netherlands.
  • McLean C; Janssen Infectious Diseases and Vaccines, Leiden, The Netherlands.
  • Goldstein N; Janssen Infectious Diseases and Vaccines, Leiden, The Netherlands.
  • Bart S; Optimal Research, LLC, Rockville, Maryland, United States of America.
  • Gaddah A; Janssen Infectious Diseases and Vaccines, Beerse, Belgium.
  • Anumenden D; Janssen Infectious Diseases and Vaccines, Beerse, Belgium.
  • Stoop JN; Janssen Infectious Diseases and Vaccines, Leiden, The Netherlands.
  • Marit de Groot A; Janssen Infectious Diseases and Vaccines, Leiden, The Netherlands.
  • Pau MG; Janssen Infectious Diseases and Vaccines, Leiden, The Netherlands.
  • Hendriks J; Janssen Infectious Diseases and Vaccines, Leiden, The Netherlands.
  • De Rosa SC; Vaccine and Infectious Disease Division, Fred Hutchinson Cancer Research Center, Seattle, Washington, United States of America.
  • Cohen KW; Vaccine and Infectious Disease Division, Fred Hutchinson Cancer Research Center, Seattle, Washington, United States of America.
  • McElrath MJ; Vaccine and Infectious Disease Division, Fred Hutchinson Cancer Research Center, Seattle, Washington, United States of America.
  • Callendret B; Janssen Infectious Diseases and Vaccines, Leiden, The Netherlands.
  • Luhn K; Janssen Infectious Diseases and Vaccines, Leiden, The Netherlands.
  • Douoguih M; Janssen Infectious Diseases and Vaccines, Leiden, The Netherlands.
  • Robinson C; Janssen Infectious Diseases and Vaccines, Leiden, The Netherlands.
PLoS One ; 17(10): e0274906, 2022.
Article in En | MEDLINE | ID: mdl-36197845
Subject(s)
Fulltext
Print
XML
PubMed Links
Search on Google

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Hemorrhagic Fever, Ebola / Ebola Vaccines / Ebolavirus / Marburgvirus Type of study: Clinical_trials Limits: Adolescent / Adult / Animals / Humans / Middle aged Language: En Journal: PLoS One Journal subject: CIENCIA / MEDICINA Year: 2022 Type: Article Affiliation country: Netherlands
Fulltext
Print
XML
PubMed Links
Search on Google

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Hemorrhagic Fever, Ebola / Ebola Vaccines / Ebolavirus / Marburgvirus Type of study: Clinical_trials Limits: Adolescent / Adult / Animals / Humans / Middle aged Language: En Journal: PLoS One Journal subject: CIENCIA / MEDICINA Year: 2022 Type: Article Affiliation country: Netherlands